聖湘生物(688289.SH):2024年度營業收入14.97億元,同比增長48.60%
格隆匯2月27日丨聖湘生物(688289.SH)公佈2024年度業績快報,在經營業績方面,公司2024年度實現營業收入14.97億元,較上一年度同比增長48.60%。其中,呼吸道類產品營業收入較去年實現翻倍,成爲公司業績增長的重要引擎。公司開發的“傳染病數智化防控平臺”成功通過國家數字化轉型項目評審,該項目融合物聯網、雲計算、大數據和人工智能技術,實現傳染病防控的“自動化檢測、數字化監測、智能化預測”全鏈條貫通。通過“三端合一”的方式打造3小時病原核酸診斷網,即“醫院爲支撐,社區爲平臺,居家爲基礎”接續性醫療服務模式,賦能引領行業新生態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.